{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:36:45Z","timestamp":1792420605805,"version":"4.5.0"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,5,26]],"date-time":"2015-05-26T00:00:00Z","timestamp":1432598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["ED2.1.00\/03.0076"],"award-info":[{"award-number":["ED2.1.00\/03.0076"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Valganciclovir (<jats:styled-content style=\"fixed-case\">vGCV<\/jats:styled-content>) and valacyclovir (<jats:styled-content style=\"fixed-case\">vACV<\/jats:styled-content>) are used in cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) prophylaxis in renal transplant recipients. The aim of this study was to compare the economic impact of both regimens during 1\u2010year follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 117 renal transplant recipients at risk for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> were randomized to 3\u2010month prophylaxis either with <jats:styled-content style=\"fixed-case\">vGCV<\/jats:styled-content> (900\u00a0mg\/day, <jats:italic>n<\/jats:italic>\u00a0=\u00a060) or <jats:styled-content style=\"fixed-case\">vACV<\/jats:styled-content> (8\u00a0g\/day, <jats:italic>n<\/jats:italic>\u00a0=\u00a057) and their data used in a pharmacoeconomic analysis. The pharmacoeconomic evaluation involved all direct <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>\u2010related expenses in the first year after transplantation. Sensitivity analysis was employed to examine the effects of various prices of antiviral drugs and diagnostic procedures on overall <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>\u2010related costs. Simulation of the more expensive <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> healthcare perspective was performed, and a scenario involving costs of acute rejection (<jats:styled-content style=\"fixed-case\">AR<\/jats:styled-content>) was examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>\u2010related costs were significantly lower in the <jats:styled-content style=\"fixed-case\">vACV<\/jats:styled-content> arm; median United States dollars (<jats:styled-content style=\"fixed-case\">USD<\/jats:styled-content>) 3473 (3108\u20133745) vs. <jats:styled-content style=\"fixed-case\">USD<\/jats:styled-content> 5810 (4409\u20136757; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) per patient, respectively. Our data showed that the critical determinant of the major disparity between the prophylactic regimens was the prophylaxis price. Median cost of prophylaxis in the <jats:styled-content style=\"fixed-case\">vACV<\/jats:styled-content> group was <jats:styled-content style=\"fixed-case\">USD<\/jats:styled-content> 1729 (1527\u20132173) compared to <jats:styled-content style=\"fixed-case\">USD<\/jats:styled-content> 3968 (2683\u20134857) in the <jats:styled-content style=\"fixed-case\">vGCV<\/jats:styled-content> group (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). In sensitivity analysis of the overall <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>\u2010related costs, the least and the most expensive pharmacotherapy and diagnostic scenarios were used; nevertheless, the <jats:styled-content style=\"fixed-case\">vACV<\/jats:styled-content> arm remained markedly less expensive. Simulation considering the higher physician\/nurse and hospitalization fees of the <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> healthcare system and the scenario including expenditure associated with <jats:styled-content style=\"fixed-case\">AR<\/jats:styled-content> episodes also favored <jats:styled-content style=\"fixed-case\">vACV<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">VACV<\/jats:styled-content> prophylaxis for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> is associated with a significant 44% lower cost than <jats:styled-content style=\"fixed-case\">vGCV<\/jats:styled-content> at the first year after renal transplantation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12383","type":"journal-article","created":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T22:14:28Z","timestamp":1427753668000},"page":"334-341","source":"Crossref","is-referenced-by-count":15,"title":["Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective"],"prefix":"10.1111","volume":"17","author":[{"given":"M.","family":"Kacer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I Charles University Medical School and Teaching Hospital Pilsen Czech Republic"},{"name":"Biomedical Center Faculty of Medicine in Pilsen Charles University in Prague Pilsen Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kielberger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I Charles University Medical School and Teaching Hospital Pilsen Czech Republic"},{"name":"Biomedical Center Faculty of Medicine in Pilsen Charles University in Prague Pilsen Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bouda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I Charles University Medical School and Teaching Hospital Pilsen Czech Republic"},{"name":"Biomedical Center Faculty of Medicine in Pilsen Charles University in Prague Pilsen Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Reischig","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I Charles University Medical School and Teaching Hospital Pilsen Czech Republic"},{"name":"Biomedical Center Faculty of Medicine in Pilsen Charles University in Prague Pilsen Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra064928"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02824.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2006.01.015"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2002.20907.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.63"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318192ded5"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009111188"},{"issue":"2","key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00007890-200007270-00013","article-title":"Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease","volume":"70","author":"Humar A","year":"2000","journal-title":"Transplantation"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1499-z"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000160"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199306000-00013"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00735.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02031.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829df29d"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2001.00003.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335962"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01413.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012010100"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008111166"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905133401903"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-004-0275-9"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07020714"},{"key":"e_1_2_6_24_1","unstructured":"IFHP.Comparative Price Report. Variation in Medical and Hospital Prices by Country.International Federation of Health Plans.2012. Available atwww.ifhp.com(accessed March 26 2013)."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318255f839"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03611.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03074.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200011270-00012"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2004.00168.x"},{"issue":"9","key":"e_1_2_6_30_1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/TP.0b013e31822fa4b7","article-title":"Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high risk solid organ transplant recipients","volume":"92","author":"Lisboa LF","year":"2011","journal-title":"Transplantation"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318200b9f0"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181bc0301"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1879"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000121763.44137.FA"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12383","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T10:09:08Z","timestamp":1696154948000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,26]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/tid.12383"],"URL":"https:\/\/doi.org\/10.1111\/tid.12383","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,26]]}}}